BackNeuroSense Therapeutics Overview

NeuroSense Therapeutics Selling, General & Admin

Selling, General & Admin expenses for NRSN.

Quarterly SG&A Expenses

$1.09M
↓ 25.09% YoY

As of Jun 30, 2025

Annual SG&A Expenses (TTM)

$3.82M
↓ 26.17% YoY

Trailing 12 months ending Jun 30, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin